{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:49:30Z","timestamp":1786650570205,"version":"build-2736575974"},"reference-count":65,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Viruses"],"abstract":"<jats:p>Letermovir (LMV), a cytomegalovirus (CMV) terminase inhibitor, has a potentially low genetic barrier to the emergence of resistance, with single mutations in the terminase subunits (UL51, UL56, UL89) being associated with LMV resistance (LMV-R). We determined the fitness of LMV-R viruses (UL56 C325F\/W\/Y or M236V mutants) with different DNA polymerase (pol) (UL54) mutants in the presence and absence of anti-CMV drugs in dual-infection competition assays. After 7 days of growth, viral variants were quantified by targeted sequencing of the UL54 or UL56 genes by next-generation sequencing. Without antivirals, the UL56 C325F mutant was equally fitted as the wild-type virus, in contrast to C325W\/Y mutants that had a reduced replication capacity. The UL56 C325F mutant showed the highest replication capacity among all terminase mutants tested when grown in competition with wild-type virus under LMV. The UL56 terminase mutants gained replication capacity when grown in competition with DNA pol mutant viruses under LMV pressure, with the terminase mutant UL56 C325F being able to overgrow various DNA pol mutants. Furthermore, the UL56 C325F mutant showed the highest replication capacity when grown in competition with another UL56 terminase mutant. Our results are in line with the C325F UL56 mutant being the most frequent LMV-R mutation identified in the clinic.<\/jats:p>","DOI":"10.3390\/v18070779","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:08:34Z","timestamp":1784189314000},"page":"779","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Competitive Fitness of Cytomegalovirus Mutants Bearing Changes in the UL56 Terminase Subunit, Associated with Letermovir-Resistance, in Presence and Absence of Antivirals"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2609-4896","authenticated-orcid":false,"given":"Graciela","family":"Andrei","sequence":"first","affiliation":[{"name":"Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1046-8431","authenticated-orcid":false,"given":"Sarah","family":"Gillemot","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Snoeck","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"E451","DOI":"10.1016\/S1473-3099(25)00069-6","article-title":"Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies","volume":"25","author":"Ljungman","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(23)00344-7","article-title":"Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Russo","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/ejh.14258","article-title":"Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A single center experience","volume":"113","author":"Desai","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.bbmt.2020.01.027","article-title":"Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the French Compassionate Program","volume":"26","author":"Robin","year":"2020","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.idc.2023.10.001","article-title":"Updates in Cytomegalovirus Prevention and Treatment in Solid Organ Transplantation","volume":"37","author":"Doss","year":"2023","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e14279","DOI":"10.1111\/tid.14279","article-title":"Evaluating the efficacy and safety of letermovir compared to valganciclovir for the prevention of human cytomegalovirus disease in adult lung transplant recipients","volume":"26","author":"Martinez","year":"2024","journal-title":"Transpl. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e15142","DOI":"10.1111\/ctr.15142","article-title":"Real world experience with conversion from valganciclovir to letermovir for cytomegalovirus prophylaxis: Letermovir reverses leukopenia and avoids mycophenolate dose reduction","volume":"37","author":"Jorgenson","year":"2023","journal-title":"Clin. Transpl."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e14337","DOI":"10.1111\/tid.14337","article-title":"Use of letermovir for cytomegalovirus primary prophylaxis in lung transplant recipients","volume":"26","author":"Kleiboeker","year":"2024","journal-title":"Transpl. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1097\/TP.0000000000005374","article-title":"The Fourth International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation","volume":"109","author":"Kotton","year":"2025","journal-title":"Transplantation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/idr16010005","article-title":"Management of Cytomegalovirus Infections in the Era of the Novel Antiviral Players, Letermovir and Maribavir","volume":"16","author":"Piret","year":"2024","journal-title":"Infect. Dis. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e02337-18","DOI":"10.1128\/AAC.02337-18","article-title":"Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis","volume":"63","author":"Turner","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s44259-025-00118-y","article-title":"Cytomegalovirus infection and drug resistance emergence during letermovir salvage therapy in a pediatric SCID patient","volume":"3","author":"Horsten","year":"2025","journal-title":"npj Antimicrob. Resist."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/infdis\/jiz577","article-title":"Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients","volume":"221","author":"Douglas","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_15","first-page":"2253","article-title":"Letermovir breakthroughs during the French Named Patient Programme: Interest of monitoring blood concentration in clinical practice","volume":"75","author":"Alain","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e13187","DOI":"10.1111\/tid.13187","article-title":"Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience","volume":"21","author":"Lin","year":"2019","journal-title":"Transpl. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1111\/ajt.16718","article-title":"Letermovir in lung transplant recipients with cytomegalovirus infection: A retrospective observational study","volume":"21","author":"Veit","year":"2021","journal-title":"Am. J. Transpl."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2019.01.011","article-title":"Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance","volume":"163","author":"Piret","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"10334","DOI":"10.1038\/s41598-025-94809-1","article-title":"Identification of a binding pocket of letermovir in the terminase subunit pUL56 of human cytomegalovirus","volume":"15","author":"Kmetsch","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.antiviral.2018.11.005","article-title":"Targeting the terminase: An important step forward in the treatment and prophylaxis of human cytomegalovirus infections","volume":"161","author":"Gentry","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"10884","DOI":"10.1128\/JVI.05265-11","article-title":"The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase","volume":"85","author":"Goldner","year":"2011","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/rmv.344","article-title":"Human cytomegalovirus terminase as a target for antiviral chemotherapy","volume":"12","author":"Bogner","year":"2002","journal-title":"Rev. Med. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"105422","DOI":"10.1016\/j.antiviral.2022.105422","article-title":"Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing","volume":"207","author":"Chou","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Pascua, P.N., Marathe, B.M., Burnham, A.J., Vogel, P., Webby, R.J., Webster, R.G., and Govorkova, E.A. (2016). Competitive Fitness of Influenza B Viruses Possessing E119A and H274Y Neuraminidase Inhibitor Resistance-Associated Substitutions in Ferrets. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0159847"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/JVI.78.2.603-611.2004","article-title":"Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants","volume":"78","author":"Collins","year":"2004","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1128\/JVI.02473-14","article-title":"Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium","volume":"89","author":"Burnham","year":"2015","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Worwa, G., Hutton, A.A., Brault, A.C., and Reisen, W.K. (2019). Comparative fitness of West Nile virus isolated during California epidemics. PLoS Negl. Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0007135"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/jmv.20557","article-title":"The contribution of HIV fitness to the evolution pattern of reverse transcriptase inhibitor resistance","volume":"78","author":"Paintsil","year":"2006","journal-title":"J. Med. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3851\/IMP1565","article-title":"Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity","volume":"15","author":"Martin","year":"2010","journal-title":"Antivir. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1128\/AAC.00259-10","article-title":"Differentiation between polymorphisms and resistance-associated mutations in human cytomegalovirus DNA polymerase","volume":"54","author":"Chevillotte","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.antiviral.2019.06.004","article-title":"Persistent primary cytomegalovirus infection in a kidney transplant recipient: Multi-drug resistant and compartmentalized infection leading to graft loss","volume":"168","author":"Andrei","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00430-021-00722-5","article-title":"Human cytomegalovirus multiple-strain infections and viral population diversity in haematopoietic stem cell transplant recipients analysed by high-throughput sequencing","volume":"210","author":"Dhingra","year":"2021","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/TP.0000000000005209","article-title":"Dynamics and Evolution of Donor-derived Cytomegalovirus Infection in 3 Solid Organ Transplant Recipients With the Same Multiorgan Donor","volume":"109","author":"Horsten","year":"2025","journal-title":"Transplantation"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/infdis\/jix157","article-title":"Characterization of Human Cytomegalovirus Genome Diversity in Immunocompromised Hosts by Whole-Genome Sequencing Directly From Clinical Specimens","volume":"215","author":"Hage","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.1073\/pnas.1818130116","article-title":"Human cytomegalovirus haplotype reconstruction reveals high diversity due to superinfection and evidence of within-host recombination","volume":"116","author":"Cudini","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"104901","DOI":"10.1016\/j.antiviral.2020.104901","article-title":"Viral fitness of MHV-68 viruses harboring drug resistance mutations in the protein kinase or thymidine kinase","volume":"182","author":"Trompet","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1093\/jac\/dkac297","article-title":"Heterogeneity and viral replication fitness of HSV-1 clinical isolates with mutations in the thymidine kinase and DNA polymerase","volume":"77","author":"Schalkwijk","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/infdis\/jiad184","article-title":"A Herpes Simplex Virus 1 DNA Polymerase Multidrug Resistance Mutation Identified in a Patient With Immunodeficiency and Confirmed by Gene Editing","volume":"228","author":"Schalkwijk","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Schalkwijk, H.H., Gillemot, S., Frobert, E., Morfin, F., Ducastelle, S., Conrad, A., Fiten, P., Opdenakker, G., Snoeck, R., and Andrei, G. (2025). Primary HSV-2 Infection in an Immunocompromised Patient Reveals High Diversity of Drug-Resistance Mutations in the Viral DNA Polymerase. Viruses, 17.","DOI":"10.3390\/v17070962"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jcv.2011.01.004","article-title":"Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy","volume":"50","author":"Chou","year":"2011","journal-title":"J. Clin. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"105181","DOI":"10.1016\/j.antiviral.2021.105181","article-title":"Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility","volume":"195","author":"Chou","year":"2021","journal-title":"Antivir. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1128\/AAC.03214-14","article-title":"Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing","volume":"58","author":"Chou","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1128\/JCM.02205-14","article-title":"Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping","volume":"52","author":"Drouot","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/375743","article-title":"Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus","volume":"188","author":"Chou","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1128\/AAC.00165-09","article-title":"Fluorescence-based assay for phenotypic characterization of human cytomegalovirus polymerase mutations regarding drug susceptibility and viral replicative fitness","volume":"53","author":"Chevillotte","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2017.10.019","article-title":"A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","volume":"148","author":"Chou","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1128\/AAC.01794-13","article-title":"Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure","volume":"58","author":"Goldner","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e0019122","DOI":"10.1128\/spectrum.00191-22","article-title":"Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients","volume":"10","author":"Tilloy","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1006\/viro.1998.9299","article-title":"A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture","volume":"248","author":"Cihlar","year":"1998","journal-title":"Virology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1128\/jvi.70.3.1390-1395.1996","article-title":"Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS","volume":"70","author":"Baldanti","year":"1996","journal-title":"J. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1099\/0022-1317-81-3-639","article-title":"Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene","volume":"81","author":"Andrei","year":"2000","journal-title":"J. Gen. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1128\/AAC.49.3.1081-1086.2005","article-title":"Susceptibilities of several clinical Varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides","volume":"49","author":"Andrei","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Balzarini, J., Andrei, G., Balestra, E., Huskens, D., Vanpouille, C., Introini, A., Zicari, S., Liekens, S., Snoeck, R., and Holy, A. (2013). A multi-targeted drug candidate with dual anti-HIV and anti-HSV activity. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003456"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1128\/JVI.06620-11","article-title":"In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs","volume":"86","author":"Andrei","year":"2012","journal-title":"J. Virol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Trompet, E., Temblador, A., Gillemot, S., Topalis, D., Snoeck, R., and Andrei, G. (2021). An MHV-68 Mutator Phenotype Mutant Virus, Confirmed by CRISPR\/Cas9-Mediated Gene Editing of the Viral DNA Polymerase Gene, Shows Reduced Viral Fitness. Viruses, 13.","DOI":"10.3390\/v13060985"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"12422","DOI":"10.1128\/JVI.02231-13","article-title":"Evaluation of novel acyclic nucleoside phosphonates against human and animal gammaherpesviruses revealed an altered metabolism of cyclic prodrugs upon Epstein-Barr virus reactivation in P3HR-1 cells","volume":"87","author":"Coen","year":"2013","journal-title":"J. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/infdis\/jix605","article-title":"The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase","volume":"217","author":"Andrei","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Jung, S., Michel, M., Stamminger, T., and Michel, D. (2019). Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4016-1"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1399-0012.2007.00761.x","article-title":"Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: Therapeutic implications and outcomes","volume":"22","author":"Eid","year":"2008","journal-title":"Clin. Transpl."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.2147\/DDDT.S265644","article-title":"Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients","volume":"18","author":"Razonable","year":"2024","journal-title":"Drug Des. Devel Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin. Transpl."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"veae101","DOI":"10.1093\/ve\/veae101","article-title":"Combined use of pritelivir with acyclovir or foscarnet suppresses evolution of HSV-1 drug resistance","volume":"10","author":"Schalkwijk","year":"2024","journal-title":"Virus Evol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e00110-24","DOI":"10.1128\/aac.00110-24","article-title":"Combination of ganciclovir and trifluridine prevents drug-resistance emergence in HSV-1","volume":"68","author":"Schalkwijk","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.antiviral.2018.08.015","article-title":"In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus","volume":"158","author":"Markovich","year":"2018","journal-title":"Antivir. Res."}],"updated-by":[{"DOI":"10.3390\/v18080888","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000}}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/7\/779\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:15:07Z","timestamp":1786608907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/7\/779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":65,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["v18070779"],"URL":"https:\/\/doi.org\/10.3390\/v18070779","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]}}}